TY - JOUR
T1 - Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer
AU - Kumar, Rajendra
AU - Mendonca, Janet
AU - Owoyemi, Olutosin
AU - Boyapati, Kavya
AU - Thomas, Naiju
AU - Kanacharoen, Suthicha
AU - Coffey, Max
AU - Topiwala, Deven
AU - Gomes, Carolina
AU - Ozbek, Busra
AU - Jones, Tracy
AU - Rosen, Marc
AU - Dong, Liang
AU - Wiens, Sadie
AU - Brennen, W. Nathaniel
AU - Isaacs, John T.
AU - Marzo, Angelo M.De
AU - Markowski, Mark C.
AU - Antonarakis, Emmanuel S.
AU - Qian, David Z.
AU - Pienta, Kenneth J.
AU - Pardoll, Drew M.
AU - Carducci, Michael A.
AU - Denmeade, Samuel R.
AU - Kachhap, Sushant K.
N1 - Funding Information:
We thank Sabatini and Lander for pCW-Cas9 (Addgene#50661) and pLXsgRNA (Addgene#50662), Trono for pMD2.G (Addgene 12259) and psPAX2 (Addgene#12260), and Wade Harper for the NCOA4a-pHAGE-C-FLAG-HA plasmid. This work is supported by the DOD grants W81XWH1910724 to S.K. Kachhap and W81XWH-14-2-0189 to S.R. Denmeade; Allegheny Health Network-Johns Hopkins Cancer Research Fund, and the NCI CORE Grant P30CA006973. E.S. Antonarakis and S.K. Kachhap are partially supported by a PCF 2018 Challenge Award. M. Coffey was supported by the CUPID program at Hopkins. Research reported in this publication was also supported by the Office of the Director of the National Institutes of Health under award number S10OD016374 and S10OD023548.
Funding Information:
J.T. Isaacs reports a patent for Sequential treatment regimen for men with castration-resistant prostate cancer: JHU REF: [C16749] pending. A.M. De Marzo reports personal fees from Cepheid Inc. and Merck, grants from Janssen R&D and Myriad outside the submitted work. E.S. Antonarakis reports personal fees from Amgen, Astellas, Bayer, Eli Lilly; grants and personal fees from AstraZeneca, Bristol Myers-Squibb, Clovis, Janssen, Merck, and Sanofi outside the submitted work. S.R. Denmeade reports a patent for Use of testosterone as therapy for prostate cancer in sequence with antiandrogen pending. S.K. Kachhap reports a patent for C16749_P16749-01 pending. No disclosures were reported by the other authors.
Publisher Copyright:
© 2021 American Association for Cancer Research Inc.. All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - The discovery that androgens play an important role in the progression of prostate cancer led to the development of androgen deprivation therapy (ADT) as a first line of treatment. However, paradoxical growth inhibition has been observed in a subset of prostate cancer upon administration of supraphysiologic levels of testosterone (SupraT), both experimentally and clinically. Here we report that SupraT activates cytoplasmic nucleic acid sensors and induces growth inhibition of SupraT-sensitive prostate cancer cells. This was initiated by the induction of two parallel autophagymediated processes, namely, ferritinophagy and nucleophagy. Consequently, autophagosomal DNA activated nucleic acid sensors converge on NFkB to drive immune signaling pathways. Chemokines and cytokines secreted by the tumor cells in response to SupraT resulted in increased migration of cytotoxic immune cells to tumor beds in xenograft models and patient tumors. Collectively, these findings indicate that SupraT may inhibit a subset of prostate cancer by activating nucleic acid sensors and downstream immune signaling. Significance: This study demonstrates that supraphysiologic testosterone induces two parallel autophagy-mediated processes, ferritinophagy and nucleophagy, which then activate nucleic acid sensors to drive immune signaling pathways in prostate cancer. _2021 American Association for Cancer Research.
AB - The discovery that androgens play an important role in the progression of prostate cancer led to the development of androgen deprivation therapy (ADT) as a first line of treatment. However, paradoxical growth inhibition has been observed in a subset of prostate cancer upon administration of supraphysiologic levels of testosterone (SupraT), both experimentally and clinically. Here we report that SupraT activates cytoplasmic nucleic acid sensors and induces growth inhibition of SupraT-sensitive prostate cancer cells. This was initiated by the induction of two parallel autophagymediated processes, namely, ferritinophagy and nucleophagy. Consequently, autophagosomal DNA activated nucleic acid sensors converge on NFkB to drive immune signaling pathways. Chemokines and cytokines secreted by the tumor cells in response to SupraT resulted in increased migration of cytotoxic immune cells to tumor beds in xenograft models and patient tumors. Collectively, these findings indicate that SupraT may inhibit a subset of prostate cancer by activating nucleic acid sensors and downstream immune signaling. Significance: This study demonstrates that supraphysiologic testosterone induces two parallel autophagy-mediated processes, ferritinophagy and nucleophagy, which then activate nucleic acid sensors to drive immune signaling pathways in prostate cancer. _2021 American Association for Cancer Research.
UR - http://www.scopus.com/inward/record.url?scp=85118601655&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118601655&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-3607
DO - 10.1158/0008-5472.CAN-20-3607
M3 - Article
C2 - 34645612
AN - SCOPUS:85118601655
SN - 0008-5472
VL - 81
SP - 5948
EP - 5962
JO - Cancer Research
JF - Cancer Research
IS - 23
ER -